PT - JOURNAL ARTICLE AU - Jun Li AU - Chulze Kong AU - Donghui Liu AU - Yuyan Zhu TI - Prognosis-Related Analysis of Renal Pelvic Cancer DP - 2004 Jun 01 TA - Chinese Journal of Clinical Oncology PG - 202--206 VI - 1 IP - 3 4099 - http://www.cancerbiomed.org/content/1/3/202.short 4100 - http://www.cancerbiomed.org/content/1/3/202.full SO - Cancer Biol Med2004 Jun 01; 1 AB - OBJECTIVE To promote the diagnosis and therapeutic results for renal pelvic cancer.METHODS The prognosis-related factors in 47 cases with renal pelvic cancer were analyzed retrospectively.RESULTS The overall 3 and 5-year survival rates for renal pelvic cancer patients were 65.9% (31/47) and 51.1 % (24/47), respectively. The 5-year survival was 55% (23/40) in organ-confined cancer and 26.7% (2/7) with coexisting multi-organ involvement (P>0.05). The 5-year survival was 33.7% (12/31) in cases with a tumor >2.5 cm and 75%(12/16) in the cases with tumor ≤2.5 cm (P<0 05). The 5-year survival was 37.9% (11/29) in cases with serious hydronephrosis, which was significantly lower than the 72.2% (13/18) found in those with slight hydronephrosis (P <0.05). According to the histological grade, the 5-year survival was 100% (6/6) in patients with a G1 tumor, 65.2% (15/23) with G2, and 16.7% (3/18) with G3 (P<0.01). Based on the pathologic stage, the 5-year survival of cases was 84.6% (11/13) with T1 tumors, 60% (12/20) with T2, and 7.1% (1/14) with T3-T4 (P<0.01). Patients with a G2T2 or higher staging tumor, who underwent radical nephroureterectomy with partial bladder resection by a transabdominai approach had a significantly higher 5-year survival than those who underwent nephrectomy or nephroureterectomy with partial bladder resection via a lumbar approach (P <0.05). There was no significant difference between the 5-year survival of patients with recurrence of bladder carcinoma compared to patients without recurrence (P> 0.05).CONCLUSION The tumor grade and stage are the key points for prognosis. Radical nephroureterectomy with partial bladder resection is an effective method to improve the prognosis of patients with a high grade and high stage tumor.